A nasal COVID-19 vaccine developed by US biotech CyanVac has produced encouraging results in an early trial, showing potential to offer broader immunity and easier delivery than current injections.

Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox ...

A mid-stage trial of BPL‑003 nasal spray shows promising results for treatment-resistant depression, igniting biotech ...

Discover today's top 10 stocks in focus, key Q1 earnings, and major corporate actions - explore the latest market movers now!

A nasal spray for treatment-resistant depression has delivered strong clinical results and rekindled investor hopes.

Lupin launches Ipratropium Bromide Nasal Solution in the US market; eyes expanding complex generics pipeline to over 200 ...

A panelist discusses how a prospective study demonstrated that twice-daily use of a nasal spray significantly improved tear ...

Lupin introduces ipratropium bromide nasal solution, 0.03% & 0.06% in US markets: Our Bureau, Mumbai Friday, July 4, 2025, 17:30 Hrs [IST] Global pharma major Lupin Limited (Lupin ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

BPL-003 showed “robust” efficacy data in treatment-resistant depression, according to analysts from Jefferies, who noted that ...

Vending machines throughout Denver have distributed more than 1,800 free boxes of the overdose reversal medication naloxone since they debuted in April.